|
|
Post by boca1girl on Apr 29, 2021 7:53:24 GMT -5
A migraine drug has been mentioned and included in MNKD’s pipeline in the past, but not for RLS that I recall.
|
|
|
|
Post by brentie on Apr 29, 2021 9:04:42 GMT -5
|
|
|
|
Post by sayhey24 on Apr 29, 2021 9:19:53 GMT -5
Hope springs eternal for RLS. Its been a long road. Maybe one day MNKD's pps will be more like GWPH's $200+. I have never fully understood the relationship between MNKD and RLS and how tight these efforts are. Andrea seemed to be working for MNKD and RLS at the same time, in the beginning. RLS was also doing CBD extraction in Danbury in the beginning before being moved to CA. Its been a mystery but it looks like it may becoming reality. MNKD royalties (or however classified) are capped at $100 million from RLS. Far from being in perpetuity. Not complaining, just saying ... Wow! - how did I miss that its capped at $100M - if so that makes me sad. Is the $100M for all the products or by product? |
|
|
|
Post by anderson on Apr 29, 2021 9:33:35 GMT -5
sumatriptan was the MNKD migraine drug.
Now it says Cystic fibrosis
|
|
|
|
Post by neil36 on Apr 29, 2021 9:34:36 GMT -5
Sayhey,
The quote below is from the January 2016 Mannkind press release. The agreement with RLS has $102.25 million in milestone payments and then royalty payments on sales. I’m not aware of any update that caps the money flow to MNKD.
————-
Under the terms of the agreement, MannKind will perform initial formulation studies and will work with Receptor to develop inhaled formulations of certain undisclosed compounds. MannKind will also transfer manufacturing technology to the licensee, who will be responsible for manufacturing and commercialization activities. The parties will collaborate on the clinical development of investigational products, with Receptor being responsible for all development costs. MannKind will be eligible to receive development and commercialization milestones of up to $102.25 million as well as mid-single to low double-digit royalties on net sales of product.
|
|
|
|
Post by anderson on Apr 29, 2021 9:53:01 GMT -5
MNKD royalties (or however classified) are capped at $100 million from RLS. Far from being in perpetuity. Not complaining, just saying ... Wow! - how did I miss that its capped at $100M - if so that makes me sad. Is the $100M for all the products or by product? Don't listen to people who dont post links to the fact:
As stated in
$100M is just for the milestones.....
And if you don't believe them, how about MNKD's offical press release: "$102.25 million as well as mid-single to low double-digit royalties on net sales of product. "
|
|
|
|
Post by sayhey24 on Apr 29, 2021 10:02:07 GMT -5
Thank you - I was feeling very sad. I am much happier now. Matt Pfiefer talked about 13% on the royalties. I am not sure that stuck but it would be better than 6%.
|
|
|
|
Post by mango on May 19, 2021 6:25:51 GMT -5
|
|
|
|
Post by Clement on May 19, 2021 7:05:01 GMT -5
The data show DPI CBD is a lot faster than vaporization and even more so than oral. If you notice you are beginning a panic attack, you want relief ASAP!
Final conclusion:
"The DPI CBD formulation is ideal for acute indications including pain, opioid craving, anxiety, and behavior disorders."
|
|
/production/original_573352236.gif)
